Literature DB >> 27278234

Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice.

Guro Søe Eriksen1, Jannike Mørch Andersen2, Fernando Boix2, Marianne Skov-Skov Bergh2, Vigdis Vindenes2, Kenner C Rice2, Marilyn A Huestis2, Jørg Mørland2.   

Abstract

Toll-like receptor 4 (TLR4) signaling is implied in opioid reinforcement, reward, and withdrawal. Here, we explored whether TLR4 signaling is involved in the acute psychomotor-stimulating effects of heroin, 6-acetylmorphine (6-AM), and morphine as well as whether there are differences between the three opioids regarding TLR4 signaling. To address this, we examined how pretreatment with (+)-naloxone, a TLR4 active but opioid receptor (OR) inactive antagonist, affected the acute increase in locomotor activity induced by heroin, 6-AM, or morphine in mice. We also assessed the effect of pretreatment with (-)-naloxone, a TLR4 and OR active antagonist, as well as the pharmacokinetic profiles of (+) and (-)-naloxone in the blood and brain. We found that (-)-naloxone reduced acute opioid-induced locomotor activity in a dose-dependent manner. By contrast, (+)-naloxone, administered in doses assumed to antagonize TLR4 but not ORs, did not affect acute locomotor activity induced by heroin, 6-AM, or morphine. Both naloxone isomers exhibited similar concentration versus time profiles in the blood and brain, but the brain concentrations of (-)-naloxone reached higher levels than those of (+)-naloxone. However, the discrepancies in their pharmacokinetic properties did not explain the marked difference between the two isomers' ability to affect opioid-induced locomotor activity. Our results underpin the importance of OR activation and do not indicate an apparent role of TLR4 signaling in acute opioid-induced psychomotor stimulation in mice. Furthermore, there were no marked differences between heroin, 6-AM, and morphine regarding involvement of OR or TLR4 signaling. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27278234      PMCID: PMC4959094          DOI: 10.1124/jpet.116.233544

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

3.  Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice.

Authors:  Fernando Boix; Jannike M Andersen; Jørg Mørland
Journal:  Addict Biol       Date:  2011-04-11       Impact factor: 4.280

Review 4.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

5.  Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia.

Authors:  G C Rossi; G P Brown; L Leventhal; K Yang; G W Pasternak
Journal:  Neurosci Lett       Date:  1996-09-20       Impact factor: 3.046

6.  dextro-Naloxone or levo-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism.

Authors:  Hsiang-En Wu; Han-Sen Sun; Caleb W Cheng; Maia Terashvili; Leon F Tseng
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

7.  Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving.

Authors:  Florence R Theberge; Xuan Li; Sarita Kambhampati; Charles L Pickens; Robyn St Laurent; Jennifer M Bossert; Michael H Baumann; Mark R Hutchinson; Kenner C Rice; Linda R Watkins; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

8.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

9.  Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4.

Authors:  X Wang; Y Zhang; Y Peng; M R Hutchinson; K C Rice; H Yin; L R Watkins
Journal:  Br J Pharmacol       Date:  2016-02-04       Impact factor: 8.739

10.  3-Methoxynaltrexone is not a selective antagonist for the acute psychomotor stimulating effects of heroin and 6-monoacetylmorphine in mice.

Authors:  Guro Søe Eriksen; Jannike Mørch Andersen; Fernando Boix; Jørg Mørland
Journal:  Pharmacol Biochem Behav       Date:  2014-03-31       Impact factor: 3.533

View more
  1 in total

1.  A further assessment of a role for Toll-like receptor 4 in the reinforcing and reinstating effects of opioids.

Authors:  Kai Yue; Gianluigi Tanda; Jonathan L Katz; Claudio Zanettini
Journal:  Behav Pharmacol       Date:  2020-04       Impact factor: 2.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.